AKS-562c
With our Ambifect™ protein therapeutic platform, Akston has developed a modified version of glucagon-like peptide-1, or GLP-1 to treat obesity in cats. The Fc binds to and activates cells bearing the GLP-1 receptor causing signaling to the brain, leading to increased satiety, decreased appetite, and decreased food intake resulting in increased weight loss.